Boston Scientific eyes FDA with new leads

Boston Scientific ($BSX) has launched a U.S. trial of two next-generation leads for defibrillators and pacemakers, working toward FDA approval after completing the first implant. The devices, Acuity X4 for pacers and Reliance 4-Front for ICDs, are quadripolar technologies, designed to maximize effectiveness by offering more flexible stimulation. Both are already CE marked and on the market overseas. More

Suggested Articles

J.D. Power aims to set the benchmarks in telehealth satisfaction with a new study due this November.

Atomwise plans to screen up to 10 billion virtual compounds for therapies against childhood cancer in collaboration with chemical supplier Enamine.

The Chan Zuckerberg Initiative set aside $68 million for over three dozen projects in an effort to map out every type of cell in the body.